title: Inhibition of normal lymphocyte proliferation by Indirubin-3'-monoxime: a multifactorial process.
abstract: Indirubin-3'-monoxime (IO) is a derivative of Indirubin, compound of a Chinese medicinal recipe used to treat various diseases including leukemia. In this study, we investigated to what extent IO inhibits the growth of normal human lymphocytes. We defined various experimental conditions of peripheral blood lymphocyte treatment: IO introduced (i) on unstimulated lymphocytes, (ii) or on stimulated lymphocytes at the time of phytohemagglutinin stimulation (L1 protocol), (iii) 48 h after the beginning of stimulation (L2 protocol), and (iv) after nocodazole synchronization of stimulated lymphocytes. IO induces a concentration dependent cytotoxic effect yielding a characteristic sub-G1 peak in normal stimulated lymphocytes. Cell death was partly due to necrosis and apoptosis. Normal unstimulated lymphocytes remained insensitive to the cytotoxic effect of 10 microM IO treatment. A cell cycle inhibition was observed after IO treatment, stronger for the L1 than for the L2 protocol, without induction of polyploidy after Nocodazole synchronization. These cellular consequences were associated with a decrease in CDK activity, and with CDK and cyclin gene expression modifications. The inhibition of lymphocyte proliferation by IO indicates that indirubin derivatives may be potent immunosuppressive agents.
authors: University Lyon1 Equipe d'Accueil 3737, Faculté, Lyon-Sud, Oullins, France.
authors: S
authors: S
authors: Kagialis-Girard
authors: V
authors: V
authors: Mialou
authors: A
authors: A
authors: Chebel
authors: W W
authors: WW
authors: Chien
authors: I
authors: I
authors: Tigaud
authors: F
authors: F
authors: Mokdad
authors: C
authors: C
authors: Badiou
authors: M
authors: M
authors: Ffrench
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology; D017209:Apoptosis / Q000187:drug effects; D002453:Cell Cycle / Q000187:drug effects; D018797:Cell Cycle Proteins / Q000235:genetics / Q000378:metabolism; D049109:Cell Proliferation / Q000187:drug effects*; D002478:Cells, Cultured / Q000187:drug effects; D006801:Humans; D015151:Immunoblotting; D007211:Indoles / Q000494:pharmacology*; D008213:Lymphocyte Activation / Q000187:drug effects; D008214:Lymphocytes / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D008934:Mitogens / Q000494:pharmacology; D009336:Necrosis; D015739:Nocodazole / Q000494:pharmacology; D010091:Oximes / Q000494:pharmacology*; D010835:Phytohemagglutinins / Q000494:pharmacology; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction
chemical_list: D000970:Antineoplastic Agents; D018797:Cell Cycle Proteins; D007211:Indoles; D008934:Mitogens; D010091:Oximes; D010835:Phytohemagglutinins; D012333:RNA, Messenger; C474021:indirubin-3'-monoxime; D015739:Nocodazole